echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Failure to improve progression-free survival!

    Failure to improve progression-free survival!

    • Last Update: 2022-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compilenewborn

    Sanofi's amcenestrant breast cancer program has suffered a setback in recent days, failing a key clinical test


    On March 14, Sanofi announced the results of the clinical trial (AMEERA-3) of amcenestrant as a monotherapy for second- or multi-line treatment of ER+/HER2- advanced or metastatic breast cancer


    AMEERA-3 is an open-label phase 2 trial evaluating amcenestrant, an oral selective estrogen receptor degrader, in 367 patients with ER+/HER2- locally advanced or metastatic breast cancer who had previously received hormone therapy.


    Currently, Sanofi is continuing to advance two other amcenestrant trials


    Results of the AMEERA-3 trial were originally expected to be announced in the second quarter of 2021


    Reference source: Sanofi Long wait for pivotal data on Sanofi's oral SERD ends in failure

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.